World ADC Asia 2025 was held in Incheon, South Korea, on June 10-12, 2025. Asia is fast becoming a global leader in ADC innovation, with first-in-class ADCs, dual payloads, bispecifics, TCE-ADCs, and advanced linkers. Topics discussed at the summit included:
Latest Data Across the ADC Landscape
Clinically Validating Novel Biomarkers for Improved Patient Selection
Novel Format & Payload Conjugates
Next Generation ADCs to Reshape the Future of Oncology Care
→ Biointron’s Highlighted Points:
1. Showcasing Latest Game-Changing Data from the ADC World to Reshape the Oncology Landscape
MYTX-011, a cMET-targeting antibody-drug conjugate, demonstrated safety, tolerability, and preliminary efficacy in patients with advanced NSCLC in the phase 1 Kismet-01 dose escalation study. (Mythic Therapeutics)
ThioBridge conjugation and hydrophilic linker technology enable site-specific, stable, and manufacturable single-DAR ADCs with improved pharmacokinetics, accelerating the development of next-generation antibody-drug conjugates. (Abzena)
Dato-DXd, an ADC from the DXd platform, demonstrates clinical benefit in breast and lung cancer, with pivotal trials supporting its use in TNBC and EGFR-mutant NSCLC through a well-characterized mechanism of action. (Daiichi Sankyo)
2. Clinically Validating Novel Biomarkers for Improved Patient Selection with ADC Drug-Diagnostic Co-Development
Computational pathology enabled the discovery of a novel TROP2 NMR biomarker using AI-driven Quantitative Continuous Scoring to guide patient selection and predict clinical outcomes for Dato-DXd in NSCLC. (AstraZeneca)
Companion diagnostics played a critical role in accelerating ADC development and regulatory strategy for Teliso-V by enabling patient selection based on c-Met overexpression in NSCLC and supporting RxDx co-approval planning. (AbbVie)
3. Assessing How Novel Format & Payload Conjugates Can Deliver More Targeted & Safer Treatments to a Wider Patient Population
Degrader-Antibody Conjugates (DACs) combine targeted antibody precision with protein degradation, showing promising safety, PK/PD, and anti-tumor activity, and offering advantages over traditional ADCs through optimized linker and PROTAC design. (Orum Therapeutics)
Bi-XDC technology leverages bi-ligand synergy to expand ADC capabilities against difficult or undruggable targets, with ongoing clinical progress supporting its potential to unlock new therapeutic opportunities. (Coherent Biopharma)
4. Overcoming Resistance With Next Generation ADCs to Reshape the Future of Oncology Care
Next-generation bispecific and DLL3-targeting ADCs for lung cancer show strong preclinical efficacy in NSCLC and SCLC models, enabled by high-throughput discovery, stable linkers, optimized DAR, and enhanced antibody affinity. (Genequantum Healthcare)
High-efficacy, stable ADCs using CHO-TEM technology to site-specifically conjugate dual drug bundles, enabling high-DAR constructs that combine distinct payloads to enhance efficacy and overcome resistance. (T-E Meds)
Thank you to everyone who visited our booth at World ADC Asia 2025 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
